Article
Bacterial mutagenicity screening in the pharmaceutical industry.
Mutation research - 1 Jan 2000
Escobar P A, Kemper R A, Tarca J, Nicolette J, Kenyon M, Glowienke S, Sawant S G, Christensen J, Johnson T E, McKnight C, Ward G, Galloway S M, Custer L, Gocke E, O'Donovan M R, Braun K, Snyder R D, Mahadevan B
Abstract excerpt
Genetic toxicity testing is used as an early surrogate for carcinogenicity testing. Genetic toxicity testing is also required by regulatory agencies to be conducted prior to initiation of first in human clinical trials and subsequent marketing for most small molecule pharmaceutical compounds. To reduce the chances of advancing mutagenic pharmaceutical candidates through the drug discovery and development...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.